Landewé, Robert BM
van der Heijde, Désirée http://orcid.org/0000-0002-5781-158X
Dougados, Maxime
Baraliakos, Xenofon
Van den Bosch, Filip E
Gaffney, Karl
Bauer, Lars
Hoepken, Bengt
Davies, Owen R
de Peyrecave, Natasha
Thomas, Karen
Gensler, Lianne
Clinical trials referenced in this document:
Documents that mention this clinical trial
FRI0397 EFFICACY AND SAFETY OUTCOMES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL: RESULTS FROM THE 48-WEEK RUN-IN PART OF C-OPTIMISE
https://doi.org/10.1136/annrheumdis-2019-eular.3053
Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction (Results)
https://doi.org/10.1136/annrheumdis-2019-216839
POS0341 PERFORMANCE ANALYSIS OF A DEEP LEARNING ALGORITHM TO DETECT POSITIVE SIJ MRI ACCORDING TO THE ASAS DEFINITION IN AXSPA PATIENTS
https://doi.org/10.1136/annrheumdis-2023-eular.2357
OP0103 DOES GENDER, AGE OR SUBPOPULATION INFLUENCE THE MAINTENANCE OF CLINICAL REMISSION IN AXIAL SPONDYLOARTHRITIS FOLLOWING CERTOLIZUMAB PEGOL DOSE REDUCTION?
https://doi.org/10.1136/annrheumdis-2020-eular.2361
POS0229 DISEASE ACTIVITY AND INFLAMMATION FOLLOWING WITHDRAWAL OF CERTOLIZUMAB PEGOL TREATMENT IN AXIAL SPONDYLOARTHRITIS PATIENTS WHO DID NOT EXPERIENCE FLARES DURING THE C-OPTIMISE STUDY
https://doi.org/10.1136/annrheumdis-2021-eular.1547
POS0679 COMPARISON OF ESTABLISHED AND NEW, PRELIMINARY PROPOSED ASAS CUT-OFFS FOR INFLAMMATORY MRI LESIONS IN THE SACROILIAC JOINTS OF AXIAL SPONDYLOARTHRITIS PATIENTS AND IMPLICATIONS FOR RECRUITMENT IN CLINICAL STUDIES
https://doi.org/10.1136/annrheumdis-2023-eular.2509
Long-term efficacy and predictors of remission following adalimumab treatment in peripheral spondyloarthritis: 3-year results from ABILITY-2
https://doi.org/10.1136/rmdopen-2017-000566
Documents that mention this clinical trial
FRI0397 EFFICACY AND SAFETY OUTCOMES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL: RESULTS FROM THE 48-WEEK RUN-IN PART OF C-OPTIMISE
https://doi.org/10.1136/annrheumdis-2019-eular.3053
Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction (Results)
https://doi.org/10.1136/annrheumdis-2019-216839
POS0341 PERFORMANCE ANALYSIS OF A DEEP LEARNING ALGORITHM TO DETECT POSITIVE SIJ MRI ACCORDING TO THE ASAS DEFINITION IN AXSPA PATIENTS
https://doi.org/10.1136/annrheumdis-2023-eular.2357
OP0103 DOES GENDER, AGE OR SUBPOPULATION INFLUENCE THE MAINTENANCE OF CLINICAL REMISSION IN AXIAL SPONDYLOARTHRITIS FOLLOWING CERTOLIZUMAB PEGOL DOSE REDUCTION?
https://doi.org/10.1136/annrheumdis-2020-eular.2361
POS0229 DISEASE ACTIVITY AND INFLAMMATION FOLLOWING WITHDRAWAL OF CERTOLIZUMAB PEGOL TREATMENT IN AXIAL SPONDYLOARTHRITIS PATIENTS WHO DID NOT EXPERIENCE FLARES DURING THE C-OPTIMISE STUDY
https://doi.org/10.1136/annrheumdis-2021-eular.1547
POS0679 COMPARISON OF ESTABLISHED AND NEW, PRELIMINARY PROPOSED ASAS CUT-OFFS FOR INFLAMMATORY MRI LESIONS IN THE SACROILIAC JOINTS OF AXIAL SPONDYLOARTHRITIS PATIENTS AND IMPLICATIONS FOR RECRUITMENT IN CLINICAL STUDIES
https://doi.org/10.1136/annrheumdis-2023-eular.2509
Long-term efficacy and predictors of remission following adalimumab treatment in peripheral spondyloarthritis: 3-year results from ABILITY-2
https://doi.org/10.1136/rmdopen-2017-000566
Funding for this research was provided by:
UCB Pharma